1. 7 Ethyl 10 Hydroxycamptothecin
2. Camptosar
3. Camptothecin 11
4. Camptothecin-11
5. Cpt 11
6. Cpt-11
7. Cpt11
8. Irinotecan
9. Irinotecan Hydrochloride
10. Irrinotecan
11. Nk012 Compound
12. Sn 38
13. Sn 38 11
14. Sn-38
15. Sn-38-11
16. Sn3811
1. 86639-52-3
2. Sn-38
3. Sn 38
4. Sn 38 Lactone
5. (s)-4,11-diethyl-4,9-dihydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
6. 10-hydroxy-7-ethylcamptothecin
7. Nk 012
8. Sn38
9. 7-ethyl-10-hydroxy-20(s)-camptothecin
10. Nk012
11. Nk-012
12. Irinotecan Related Compound B
13. Chebi:8988
14. 113015-38-6
15. It-141
16. Nsc673596
17. 0h43101t0j
18. (4s)-4,11-diethyl-4,9-dihydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione
19. (+)-7-ethyl-10-hydroxycamptothecin
20. (19s)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
21. (4s)-4,11-diethyl-4,9-dihydroxy-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione
22. 7-ethyl-10-hydroxy-20(s)-campthothecin
23. Le-sn38
24. Captothecin, 7-ethyl-10-hydroxy-
25. Mfcd00871873
26. Unii-0h43101t0j
27. 110714-48-2
28. 1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4,11-diethyl-4,9-dihydroxy-, (4s)-
29. 1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, 4,11-diethyl-4,9-dihydroxy-, (4s)-
30. Avachem1025
31. Diethyl(dihydroxy)[?]dione
32. Sn 38- Bio-x
33. Schembl34018
34. Gtpl6925
35. Sn 38 [who-dd]
36. Dtxsid4040399
37. 10-hydroxy-7-ethyl Camptothecin
38. 10-hydroxy-7-ethyl-camptothecin
39. 7-ethyl-10-hydroxy Campthotecin
40. Ex-a989
41. Hms3413b12
42. Hms3652p12
43. Hms3677b12
44. Bcp01386
45. Zinc4099013
46. 7-ethyl-10-hydroxy-20(s)-cpt
47. Bdbm50418088
48. S4908
49. Akos015920433
50. Sn-38(nk-012)
51. Ac-1357
52. Bcp9000200
53. Ccg-264764
54. Cs-1579
55. Db05482
56. Nsc-673596
57. Ncgc00167831-01
58. Ncgc00167831-05
59. (4s)-4,11-diethyl-4,9-dihydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)dione
60. As-13533
61. Be164132
62. Bp-24513
63. Hy-13704
64. Nci60_026056
65. Camptothecin, 7-ethyl-10-hydroxy-
66. E0748
67. N2133
68. Sw219948-1
69. S-(+)-7-ethyl-10-hydroxycampothecin
70. Irinotecan Related Compound B [usp-rs]
71. 439e812
72. A857464
73. Q-100871
74. Q1750127
75. 7-ethyl-10-hydroxycamptothecin, >=98% (hplc), Powder
76. Irinotecan Related Compound B, United States Pharmacopeia (usp) Reference Standard
77. (19s)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
78. (4s)-4,11-diethyl-4,9-dihydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)dione, Aldrichcpr
79. (4s)-4,9-dihydroxy-4,11-diethyl-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione;sn-38
80. (s)-4,11-diethyl-4,9-di-oh-1,12-dihydro-4h-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
81. 1h-pyrano[3',7]indolizino[1,2-b]quinoline- 3,14(4h,12h)-dione, 4,11-diethyl-4,9-dihydroxy-, (4s)-
82. 7-ethyl-10-hydroxycamptothecin ((s)-4,11-diethyl-4,9-dihydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione)
83. H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4,11-diethyl-4,9-dihydroxy-, (s)-
84. Rs4
1. Sn-38
| Molecular Weight | 392.4 g/mol |
|---|---|
| Molecular Formula | C22H20N2O5 |
| XLogP3 | 1.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 2 |
| Exact Mass | 392.13722174 g/mol |
| Monoisotopic Mass | 392.13722174 g/mol |
| Topological Polar Surface Area | 100 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 820 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in colorectal cancer.
SN-38 (7-ethyl-10-hydroxycamptothecin) is the active metabolite of Irinotecan (CPT-11). Irinotecan is a topoisomerase I inhibitor commercially available as Camptosar. SN-38 has been found to be 2002000 times more cytotoxic than CPT-11, but has not been used as an anticancer drug due to its poor solubility in pharmaceutically acceptable solvents and low affinity to lipid membranes. SN-38 also undergoes a reversible conversion to an inactive open lactone ring structure at physiological pH. LE-SN-38 is a novel lipsome based formulation containing liposomes of uniform size distribution (<200 nm). Drug entrapment efficiency of the formulation is>95%.
Topoisomerase I Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)
The entrapment of SN-38 in lipsomes results in a more stable and more soluble form of the drug. This allows for increased affinity of SN-38 to lipid membranes and improved delivery of the drug to tumor sites. SN-38 is a highly effective cytotoxic topoisomerase I inhibitor.
BUILDING BLOCK
SUPPLIERS
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
7-Ethyl-10-hydroxycamptothecin (SN-38)
CAS Number : 86639-52-3
End Use API :
End Use API : Irinotecan Hydrochloride
About the Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialzation. With our expe...
7-Ethyl-10-hydroxycamptothecin
CAS Number : 86639-52-3
End Use API :
End Use API : Irinotecan Hydrochloride
About the Company : Chengdu Yazhong Bio-pharmaceutical Co., Ltd., founded in 2002, is a leading company with plant extracts, APIs and medical intermediates. Our company is equipped with GMP approved manufa...
7-Ethyl-10-hydroxycamptothecin
CAS Number : 86639-52-3
End Use API :
End Use API : Irinotecan Hydrochloride
About the Company : Jiangsu Yutian Pharmaceutical Co., Ltd. is located in Dapu Pharmaceutical Zone of Lianyungang City in Jiangsu Province. It is a new and high-tech enterprise engaged in research and prod...
END USE APIs
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
RELATED INTERMEDIATES
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulatio...
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulatio...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quali...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quali...
MARKET PLACE
APIs
Reply
31 Jul 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
LOOKING FOR A SUPPLIER?
Comment (1)
